This resulted in significantly decreased plasma D-lactate, diamine oxidase, TNF-α, IL-1β, and IL-6 levels, indicating improved intestinal barrier function and ameliorated plasma inflammation during AP (Figure 3A and Supplementary Figure S2). The gene discussed is IL1B; the disease is alkaline phosphatase measurement.